Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 411 of 5804
-
Can a Botox-Like shot stop migraines before they start?
Prevention Recruiting nowIn this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details includ…
Phase: PHASE3 • Sponsor: Merz Therapeutics GmbH • Aim: Prevention
Last updated Jun 27, 2026 14:03 UTC
-
Can a stronger radiation blast tame pancreatic cancer?
Disease control Recruiting nowThis phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care options include additional chemotherapy, …
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Triple-Drug cocktail takes on recurrent gynecologic cancers
Disease control Recruiting nowThis Phase II study is a clinical trial to evaluate the efficacy and safety of BL-B01D1 + pembrolizumab dual therapy with or without bevacizumab (BL-B01D1 + pembrolizumab ± bevacizumab) in patients with recurrent or metastatic cervical cancer and endometrial cancer.
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for tough lymphoma: experimental drug ICP-248 targets relapsed mantle cell cancer
Disease control Recruiting nowThis is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Needles vs. nausea: electroacupuncture trial aims to calm chemo side effects
Symptom relief Recruiting nowThis study aims to elucidate the therapeutic efficacy of electroacupuncture in managing chemotherapy-induced gastrointestinal symptom clusters through clinical research. Building upon this foundation, multi-omics analyses will be conducted to investigate the regulatory effects an…
Phase: PHASE3 • Sponsor: Jiuda Zhao • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC
-
Double-Barreled antibody attack aims to wipe out hidden myeloma cells
Disease control Recruiting nowMultiple myeloma is characterized by a pattern of recurrent relapse and remains an incurable malignancy. Participants with minimal residual disease (MRD) after front line therapy with induction and transplant have worse prognosis than those with MRD negative disease. Bispecific …
Phase: PHASE2 • Sponsor: Noffar Bar • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a common antibiotic slash deaths from brain TB?
Disease control Recruiting nowAlthough tuberculosis is now considered a treatable disease, central nervous system tuberculosis (CNS-TB) when managed with the current standard-of-care (SOC), still has mortality rates ranging from 30-50% even in tertiary hospital centers. At present, the SOC for the management …
Phase: PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could less radiation be better? new trial aims to reduce side effects for advanced nose cancer patients
Disease control Recruiting nowIn order to further verify the effectiveness of the new prevention irradiation model for low-risk areas for nasopharyngeal carcinoma under immunotherapy, our team intends to conduct a non-inferiority clinical trial. The aim is to evaluate the efficacy and safety of two treatment …
Phase: PHASE3 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill AVZO-023 takes on advanced breast cancer in first human trial
Disease control Recruiting nowThis study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits c…
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a $4 heart pill beat a cancer? new trial tests propranolol for kaposi sarcoma
Disease control Recruiting nowKaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). Lesion progression is driven by abnormal angiogenesis, chronic inflammation, and uncontrolled cell proliferation. KS remains one of the m…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Immunotherapy combo shows promise against tough colorectal cancer
Disease control OngoingImmunotherapy may bring revolutionary changes to the preoperative neoadjuvant treatment mode for dMMR/MSI-H locally advanced rectal cancer. According to the existing theory, the use of Iparomlimab and Tuvonralimab may be the best solution. In this study, the investigators will pe…
Phase: PHASE2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
HIV breakthrough? drug may let patients ditch daily meds
Disease control ENROLLING_BY_INVITATIONEven though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can …
Phase: PHASE2 • Sponsor: Michael Peluso, MD • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New trial tests CPAP combo to save lives in breathing crisis
Disease control Recruiting nowDe novo hypoxemic acute respiratory failure (hARF) is one of the main causes of intensive care unit (ICU) admission. In de novo hARF, intubation is associated with a dramatic increase in mortality rate. Compared to standard oxygen, the use of high-flow oxygen nasal cannula (HFNC)…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowBackground: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Researchers want to know if drug treatments that…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy targets hard-to-treat lymphoma
Disease control Recruiting nowThis study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD858…
Phase: PHASE1, PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could a few radiation sessions be enough for breast cancer?
Disease control Recruiting nowTo learn about the effects of shorter RNI regimens in patients with breast cance who have had a lumpectomy or mastectomy and who are at higher risk for lower risk for the disease returning.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Chemotherapy directly into the belly: a new hope for advanced stomach cancer?
Disease control Recruiting nowThis study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdominal cavity in addition to chemotherapy given through a vein in your arm? Will ad…
Phase: PHASE2, PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail aims to outsmart resistant prostate cancer
Disease control Recruiting nowThis research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapi…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug rilzabrutinib aims to tame rare blood disorder
Disease control Recruiting nowThis is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female participants ≥ 18 years of age with a confirmed diagn…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New scan could spot prostate cancer more accurately
Diagnosis Recruiting nowThis is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC